5 Key Takeaways

• 1

  KinetiSol technology dissolves poorly soluble drug crystals into excipients without solvents or heat, enabling previously undruggable molecules.

• 2

  Recent research has expanded KinetiSol applications to parenteral delivery and dry powder inhalation, enhancing drug solubility and delivery methods.

• 3

  KinetiSol received the Advancing Pharmacy Research Award, increasing industry recognition and validating the technology's potential.

• 4

  Challenges in small molecule drug development include rising expectations for CDMOs and pressures for cost reduction and faster turnaround times.

• 5

  The democratization of drug discovery allows small entities to innovate, but CDMOs are essential for bridging the gap to commercialization.